These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16980747)

  • 21. Anemia--a complication of antiviral treatment in chronic viral hepatitis C.
    Orāşan O; Cozma A; Rednic N; Sâmpelean D; Pârvu A; Petrov L
    Rom J Intern Med; 2009; 47(3):217-25. PubMed ID: 20446436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C.
    Sho Y; Fujisaki K; Sakashita H; Yamaguchi K; Tahara K; Kubozono O; Ido A; Tsubouchi H
    J Gastroenterol; 2004 Dec; 39(12):1202-4. PubMed ID: 15622486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy.
    Huang JF; Chuang WL; Dai CY; Chen SC; Lin ZY; Lee LP; Lee PL; Wang LY; Hsieh MY; Chang WY; Yu ML
    J Viral Hepat; 2006 Jun; 13(6):396-401. PubMed ID: 16842442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of growth factors with antiviral therapy for chronic hepatitis C.
    Curry MP; Afdhal NH
    Clin Liver Dis; 2005 Aug; 9(3):439-51, vii. PubMed ID: 16023976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy.
    Chu E; Einhorn LH; Lefebvre P
    J Support Oncol; 2006 May; 4(5):243-50. PubMed ID: 16724648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The adherence in the treatment of chronic hepatitis C].
    Pawłowska M; Halota W
    Pol Merkur Lekarski; 2005 Apr; 18(106):469-72. PubMed ID: 16161937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.
    Stickel F; Helbling B; Heim M; Geier A; Hirschi C; Terziroli B; Wehr K; De Gottardi A; Negro F; Gerlach T
    J Viral Hepat; 2012 Feb; 19(2):77-87. PubMed ID: 22239497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of anemia in human immunodeficiency virus, cancer, and hepatitis C virus.
    Mildvan D
    Clin Infect Dis; 2003; 37 Suppl 4():S293-6. PubMed ID: 14581997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of relapsers after combination therapy for chronic hepatitis C.
    Ahmed F; Jacobson IM
    Infect Dis Clin North Am; 2006 Mar; 20(1):137-53. PubMed ID: 16527653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis.
    Alavian SM; Tabatabaei SV; Behnava B
    J Viral Hepat; 2012 Feb; 19(2):88-93. PubMed ID: 22239498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating treatment of hepatitis C for hemolytic anemia management.
    DebRoy S; Kribs-Zaleta C; Mubayi A; Cardona-Meléndez GM; Medina-Rios L; Kang M; Diaz E
    Math Biosci; 2010 Jun; 225(2):141-55. PubMed ID: 20303990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
    Ong JP; Younossi ZM
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S17-21. PubMed ID: 15468613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of the hematologic complications of hepatitis C therapy.
    Sulkowski MS
    Clin Liver Dis; 2005 Nov; 9(4):601-16, vi. PubMed ID: 16207566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy.
    Berenguer M; Aguilera V; Rubín A; Ortíz C; Jimenez M; Prieto M
    J Hepatol; 2012 Jun; 56(6):1310-6. PubMed ID: 22314429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The burden of HCV treatment in patients with inherited bleeding disorders.
    Fransen van de Putte DE; Fischer K; Posthouwer D; Mauser-Bunschoten EP
    Haemophilia; 2011 Sep; 17(5):791-9. PubMed ID: 21689211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial.
    Sulkowski MS; Dieterich DT; Bini EJ; Bräu N; Alvarez D; Dejesus E; Leitz GJ;
    J Acquir Immune Defic Syndr; 2005 Aug; 39(4):504-6. PubMed ID: 16010180
    [No Abstract]   [Full Text] [Related]  

  • 37. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy.
    McHutchison JG; Manns MP; Brown RS; Reddy KR; Shiffman ML; Wong JB
    Am J Gastroenterol; 2007 Apr; 102(4):880-9. PubMed ID: 17397412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Administration of low-dose epoetin-alpha facilitates adherence to ribavirin in triple therapy with pegylated interferon-alpha-2b and telaprevir.
    Ishida H; Sakane S; Toyama T; Fukutomi K; Kimura K; Sugimoto A; Hibino K; Tamura T; Iwasaki T; Iwasaki R; Hasegawa H; Sakakibara Y; Yamada T; Nakazuru S; Mita E
    Hepatol Res; 2014 Oct; 44(10):E84-91. PubMed ID: 23957840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis.
    Spiegel BM; Chen K; Chiou CF; Robbins S; Younossi ZM
    Clin Gastroenterol Hepatol; 2005 Oct; 3(10):1034-42. PubMed ID: 16234051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of associated anemia in different hematological disorders with epoetin alpha.
    Maisnar V; Chroust K
    Neoplasma; 2004; 51(5):379-84. PubMed ID: 15640943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.